Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from China Traditional Chinese Medicine Holdings Co ( (HK:0570) ).
China Traditional Chinese Medicine Holdings Co. Limited announced that two of its traditional Chinese medicine compound preparations, Shaoyao Gancao Tang Granules and Taohe Chengqi Tang Granules, have received drug approval licenses from China’s National Medical Products Administration, clearing them for official marketing. Both formulations are modernized granule versions of ancient classic prescriptions from Zhang Zhongjing’s Treatise on Cold Pathogenic Diseases, with contemporary studies indicating therapeutic benefits for conditions ranging from musculoskeletal and gastrointestinal disorders to acute pelvic inflammatory disease, diabetes and chronic prostatitis.
The group emphasized its R&D approach of “restoring a bowl of decoction,” applying full-process quality control and modern extraction technology to preserve core active components while improving dosing convenience for patients. Management signaled that these approvals advance its strategy of systematizing classical formulae, accelerating industrialization of innovative traditional Chinese medicine and expanding clinical application, developments that could strengthen its competitive positioning in the TCM sector and support longer-term growth in prescription and hospital markets.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
More about China Traditional Chinese Medicine Holdings Co
China Traditional Chinese Medicine Holdings Co. Limited is a Hong Kong-incorporated pharmaceutical group focused on the research, development and commercialization of traditional Chinese medicine preparations. Through subsidiaries such as Sinopharm Group Guangdong Medi-World Pharmaceutical and Guangdong Yifang Pharmaceutical, it develops modern dosage-form products that translate classical herbal formulae into standardized, mass-market treatments for a broad range of clinical indications.
YTD Price Performance: -18.18%
Average Trading Volume: 13,292,349
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.61B
For detailed information about 0570 stock, go to TipRanks’ Stock Analysis page.